Colorectal Cancer Clinical Trial
Official title:
The Effectiveness of Telephone Reminders and SMS Messages on Compliance With Colorectal Cancer Screening: An Open-label, Randomized Controlled Trial
Colorectal cancer (CRC) is one of the major global health challenges. CRC is currently the
third most common cancer in men and the second common in women worldwide, accounting for
approximately 10% of all cancers.
Randomized controlled studies have shown that CRC screening using Faecal Occult Blood Testing
(FOBT) is effective in reducing cancer mortality by 15-33%. Since yearly testing is
recommended to maintain programmatic effectiveness, longitudinal adherence is a critical
component of FOBT-based screening programs. The investigators previous study conducted in
Hong Kong showed that the rate of compliance with CRC screening was declining since the first
year of enrolment.
Nevertheless, it remains unknown whether interventions based on reminder systems could
effectively enhance longitudinal compliance with FOBT, especially among those who have
already enrolled in a CRC screening programme. Current evidence does not adequately compare
whether interactive or one-way reminder messages are superior to usual care (i.e. no
reminders).
Colorectal cancer (CRC) is one of the major global health challenges. CRC is currently the
third most common cancer in men and the second common in women worldwide, accounting for
approximately 10% of all cancers. It leads to 8% of all cancer mortality in the world and it
is the fourth most common cause of cancer deaths. There were 4,563 new cases and 3,893 new
deaths in Hong Kong in 2012, while 47.4% of the new cases were diagnosed at stage III or
above. In the past decades the Asia Pacific countries like China, South Korea, Japan, and
Singapore have witnessed a two to three-fold rise in incidence, gradually catching up the
figures in Western countries. The direct medical cost for the care of colorectal neoplasia
was estimated US$45,115 for stage IV CRC in the initial year of care, bringing a substantial,
global public health burden to the healthcare systems.
Randomized controlled studies have shown that CRC screening using Faecal Occult Blood Testing
(FOBT) is effective in reducing cancer mortality by 15-33%. FOBT as a quick office-based
procedure has the advantages of being non-invasive, inexpensive, acceptable, feasible,
patient-friendly and devoid of needs for bowel preparation. A 25% relative risk reduction in
CRC mortality was found for those attending at least one round of FOBT screening, according
to a systematic review conducted in 2007. Guidelines from the US Preventive Services Task
Force, the European Nations, the Asia Pacific Consensus statements and other authorities
recommended FOBT as one of the first-line screening modalities, especially in
resource-limited regions. Since yearly testing is recommended to maintain programmatic
effectiveness, longitudinal adherence is a critical component of FOBT-based screening
programs. The investigators previous study conducted in Hong Kong showed that the rate of
compliance with CRC screening was declining since the first year of enrolment.
Nevertheless, it remains unknown whether interventions based on reminder systems could
effectively enhance longitudinal compliance with FOBT, especially among those who have
already enrolled in a CRC screening programme. Current evidence does not adequately compare
whether interactive or one-way reminder messages are superior to usual care (i.e. no
reminders).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |